Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

The Cardiovascular Workup for ED

ED as a vascular warning sign, Princeton IV and what a good evaluation looks like

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
N/A (clinical evaluation/consensus topic)

Reference only. Not medical advice.

What can go wrong

The Princeton framework also addresses the cardiac safety of resuming sexual activity and using PDE5 inhibitors: patients are risk-stratified (low/intermediate/high) for sexual-activity safety, and the absolute nitrate contraindication is central. Missing the cardiovascular signal, treating ED only as a sexual complaint, is the key error the pathway is designed to prevent.

This is something to take to a clinician. The Atlas can tell you what is known about the cardiovascular workup for ed in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Erectile dysfunction is an established marker of cardiovascular risk. Because penile arteries are smaller than coronary arteries, endothelial dysfunction can show up as ED years before a heart attack, making ED a 'canary in the coal mine.' The Princeton Consensus series (most recently Princeton IV, 2024, published in Mayo Clinic Proceedings) frames ED as a risk-enhancing factor for atherosclerotic cardiovascular disease and integrates ACC/AHA risk tools, including coronary artery calcium (CAC) scoring, into the evaluation of men presenting with ED.

An erection is a vascular event, and often the first symptom of heart disease.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Risk stratification of men with ED
  • Identifying silent coronary disease
  • Timing PDE5-inhibitor use around cardiac risk

How it works

ED and atherosclerosis share endothelial dysfunction as a root mechanism. A good evaluation therefore goes beyond writing a prescription: history (including cardiac symptoms and exercise tolerance), blood pressure, lipids, glucose/HbA1c, and ASCVD risk estimation; in low-to-intermediate-risk men, a coronary artery calcium score can reclassify risk and guide statin/risk-factor intensification. Hormonal screening (testosterone) is added where indicated.

Why CAC scoring entered the ED pathway

ED in an otherwise low-to-intermediate-risk man is a reason to look harder for subclinical atherosclerosis. Princeton IV and ACC commentary recommend considering coronary artery calcium scoring in these men to refine ASCVD risk, because a man whose only 'symptom' is ED may have silent coronary disease that changes how aggressively risk factors should be treated.

What people get wrong

  • Often saidED is just a sexual problem to fix with a pill

    ActuallyED is frequently an early marker of cardiovascular disease. A proper workup can catch silent heart disease years before a cardiac event.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Set against the alternatives

A minimal evaluation is a quick prescription and a nitrate check. A good evaluation treats ED as a cardiovascular vital sign: full risk-factor assessment, ASCVD scoring, selective CAC, hormonal labs where indicated, and risk-stratified counseling on the safety of sexual activity, converting an embarrassing complaint into a chance to prevent a heart attack.

At a glance

Core concept
ED is a marker/early sign of cardiovascular disease
Why
Penile arteries are smaller than coronary arteries
Framework
Princeton IV Consensus (2024, Mayo Clinic Proceedings)
Tools
ASCVD risk score; coronary artery calcium (CAC) in low/intermediate risk

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about The Cardiovascular Workup for ED. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Princeton IV Consensus Recommendations2024

    Frames ED as an ASCVD risk-enhancing factor; integrates ACC/AHA risk assessment and coronary artery calcium scoring into ED evaluation (Mayo Clinic Proceedings)

  • Princeton III Consensus2012

    Earlier framework linking ED management with cardiovascular risk and sexual-activity safety stratification